Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Resistance
SHV-type ESBLs confer cefepime resistance in one-third of Enterobacter cloacae isolates
December 29th, 2005
One-third of clinical Enterobacter cloacae isolates produce enzymes that strongly limit cefepime efficacy. "Cefepime is a potentially useful antibiotic" for the treatment of E. cloacae infections, physicians in the United States explained. "However, in our institution the MIC for E. cloacae bloodstream isolates is 1.6 microg/mL," noted D. Szabo and colleagues at the University of Pittsburgh Medical Center. In their study, "PCR amplification of bla genes revealed that one-third (15/45) of E. cloacae bloodstream isolates produced SHV-type extended-spectrum beta-lactamases (ESBLs) in addition to hyperproduction of...
Source: Blood Weekly (2005-12-29)
|
